CA2542192C - Look-through mutagenesis - Google Patents

Look-through mutagenesis Download PDF

Info

Publication number
CA2542192C
CA2542192C CA2542192A CA2542192A CA2542192C CA 2542192 C CA2542192 C CA 2542192C CA 2542192 A CA2542192 A CA 2542192A CA 2542192 A CA2542192 A CA 2542192A CA 2542192 C CA2542192 C CA 2542192C
Authority
CA
Canada
Prior art keywords
ser
amino acid
thr
polypeptide
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2542192A
Other languages
English (en)
French (fr)
Other versions
CA2542192A1 (en
Inventor
Roberto Crea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioren LLC
Original Assignee
Bioren LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioren LLC filed Critical Bioren LLC
Publication of CA2542192A1 publication Critical patent/CA2542192A1/en
Application granted granted Critical
Publication of CA2542192C publication Critical patent/CA2542192C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1093General methods of preparing gene libraries, not provided for in other subgroups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2542192A 2003-06-27 2004-06-25 Look-through mutagenesis Expired - Lifetime CA2542192C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48328203P 2003-06-27 2003-06-27
US60/483,282 2003-06-27
PCT/US2004/020306 WO2005003345A2 (en) 2003-06-27 2004-06-25 Look-through mutagenesis

Publications (2)

Publication Number Publication Date
CA2542192A1 CA2542192A1 (en) 2005-01-13
CA2542192C true CA2542192C (en) 2013-05-28

Family

ID=33563915

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2542192A Expired - Lifetime CA2542192C (en) 2003-06-27 2004-06-25 Look-through mutagenesis

Country Status (14)

Country Link
US (1) US20050136428A1 (enExample)
EP (1) EP1660655B1 (enExample)
JP (2) JP4791960B2 (enExample)
KR (1) KR20060034650A (enExample)
CN (1) CN1836041A (enExample)
AU (1) AU2004254352A1 (enExample)
BR (1) BRPI0412007A (enExample)
CA (1) CA2542192C (enExample)
ES (1) ES2609102T3 (enExample)
IL (1) IL172736A0 (enExample)
NO (1) NO20060108L (enExample)
RU (1) RU2005140664A (enExample)
WO (1) WO2005003345A2 (enExample)
ZA (1) ZA200510460B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329725B1 (en) * 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
ES2563491T3 (es) 2004-07-06 2016-03-15 Bioren, LLC Bibliotecas universales de anticuerpos
BRPI0513155B1 (pt) 2004-07-06 2021-07-20 Bioren, Inc. Método de distinguir um ou mais resíduos de aminoácido funcionais dos resíduos de aminoácido não-funcionais em uma região definida dentro de um polipeptídeo, método de gerar uma biblioteca de análogos de polipeptídeo e método de identificar um subconjunto de análogos de polipeptídeo tendo uma propriedade desejada
EP1769003A1 (en) * 2004-07-06 2007-04-04 Bioren, Inc. HIGH AFFINITY ANTI-TNF-alpha ANTIBODIES AND METHOD
US20060234303A1 (en) * 2005-03-03 2006-10-19 Xencor, Inc. Methods for the design of libraries of protein variants
US20080207467A1 (en) * 2005-03-03 2008-08-28 Xencor, Inc. Methods for the design of libraries of protein variants
US20090215639A1 (en) * 2005-04-26 2009-08-27 Bioren, Inc. Method of Producing Human IgG Antibodies with Enhanced Effector Functions
EP1945668A4 (en) * 2005-08-15 2009-07-22 Arana Therapeutics Ltd SYNTHETIC ANTIBODIES WITH FRAMEWORK REGIONS OF NEUWELTPRIMATEN
CA2627075A1 (en) * 2005-11-14 2007-05-18 Bioren, Inc. Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening
WO2007086994A1 (en) * 2005-11-15 2007-08-02 Balyasnikova Irina V Single chain fragment of monoclonal antibody 9b9 and uses thereof
JP2009519983A (ja) 2005-12-20 2009-05-21 アラーナ・テラピューティクス・リミテッド 部分的な新世界ザル結合領域を有するキメラ抗体
US7846439B2 (en) 2006-02-01 2010-12-07 Cephalon Australia Pty Ltd Domain antibody construct
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
WO2007112054A2 (en) * 2006-03-23 2007-10-04 Sea Lane Biotechnologies, Llc Facilitation of translocation of molecules through the gastrointestinal tract
EP2024393A2 (en) 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
WO2007136840A2 (en) * 2006-05-20 2007-11-29 Codon Devices, Inc. Nucleic acid library design and assembly
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CN103541018A (zh) * 2006-10-02 2014-01-29 航道生物技术有限责任公司 多样性合成肽和多肽文库的设计和构建
US20080287320A1 (en) * 2006-10-04 2008-11-20 Codon Devices Libraries and their design and assembly
DK2171055T3 (en) * 2007-06-06 2016-06-27 Danisco Us Inc Process for the improvement of protein many properties
WO2009009045A2 (en) * 2007-07-10 2009-01-15 The Scripps Research Institute Escape libraries of target polypeptides
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
JP5781762B2 (ja) * 2007-08-10 2015-09-24 プロテリックス、インク ユニバーサルiii型フィブロネクチン結合ドメインのライブラリ
EP2215125A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
AU2009228058A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
EP2131243B1 (en) * 2008-06-02 2015-07-01 ASML Netherlands B.V. Lithographic apparatus and method for calibrating a stage position
EP2417162A2 (en) 2009-04-10 2012-02-15 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2010115998A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
NZ597314A (en) 2009-06-05 2013-07-26 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
ES2581318T3 (es) * 2009-07-17 2016-09-05 Bioatla Llc Selección y evolución simultáneas e integradas de rendimiento y expresión de anticuerpos/proteínas en huéspedes de producción
GB0914691D0 (en) * 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
WO2011051333A1 (en) 2009-10-30 2011-05-05 Novartis Ag Universal fibronectin type iii bottom-side binding domain libraries
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP3222631A3 (en) 2010-07-30 2017-11-22 Novartis AG Fibronectin cradle molecules and libraries thereof
US9753040B2 (en) 2010-12-01 2017-09-05 Mitsubishi Tanabe Pharma Corporation Polynucleotide construct capable of displaying fab in a cell-free translation system, and method for manufacturing and screening fab using same
CA2849195A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
WO2013128031A1 (en) 2012-03-02 2013-09-06 Ablynx Nv Pseudomonas aeruginosa pcrv binding single variable domain antibodies
USRE49477E1 (en) * 2012-04-20 2023-03-28 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
TR201910420T4 (tr) 2012-05-25 2019-08-21 Chr Hansen As Geliştirilmiş süt pıhtılaştırma niteliklerine sahip kimozin varyantları.
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
CN104955961B (zh) * 2012-12-11 2017-03-08 塞勒密斯株式会社 利用密码子随机化和诱变来合成基因文库的方法
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
EP3062818B1 (en) * 2013-11-01 2019-09-11 IBC Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
CN104805507B (zh) * 2014-01-29 2019-01-22 杭州康万达医药科技有限公司 噬菌体展示文库及其应用和制备方法
NZ722003A (en) 2014-02-26 2023-06-30 Chr Hansen As Variants of chymosin with improved milk-clotting properties
AU2015334984A1 (en) 2014-10-21 2017-04-13 Ablynx Nv Treatment of IL-6R related diseases
US11174473B2 (en) 2015-06-22 2021-11-16 Chr. Hansen A/S Variants of chymosin with improved properties
WO2017037092A1 (en) 2015-08-31 2017-03-09 Chr. Hansen A/S Variants of chymosin with improved properties
KR102699793B1 (ko) * 2016-01-08 2024-08-27 모모타로겐 가부시키가이샤 REIC/Dkk-3 유전자 및 체크포인트 저해제를 이용한 병용 요법
JP7084317B2 (ja) 2016-05-19 2022-06-14 セーホーエル.ハンセン アクティーゼルスカブ 改善された凝乳特性を有するキモシン変異体
US10954505B2 (en) 2016-05-19 2021-03-23 Chr. Hansen A/S Variants of chymosin with improved milk-clotting properties
EP4282969A3 (en) 2016-09-02 2024-01-31 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
KR102847676B1 (ko) 2017-12-15 2025-08-21 알레타 바이오쎄라퓨틱스, 인크. Cd19 변이체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0527809B1 (en) * 1990-04-05 1995-08-16 CREA, Roberto Walk-through mutagenesis
EP0748338A4 (en) * 1994-03-04 2001-03-28 Merck & Co Inc IN VITRO MATURATION OF ANTIBODIES BY MEANS OF ALANINE 'SCANNING' MUTAGENESIS
US20030180714A1 (en) * 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning

Also Published As

Publication number Publication date
AU2004254352A1 (en) 2005-01-13
JP2007524390A (ja) 2007-08-30
EP1660655A2 (en) 2006-05-31
WO2005003345A2 (en) 2005-01-13
JP4791960B2 (ja) 2011-10-12
CN1836041A (zh) 2006-09-20
NO20060108L (no) 2006-03-24
CA2542192A1 (en) 2005-01-13
IL172736A0 (en) 2006-04-10
KR20060034650A (ko) 2006-04-24
US20050136428A1 (en) 2005-06-23
WO2005003345A3 (en) 2005-03-24
ES2609102T3 (es) 2017-04-18
JP2011182794A (ja) 2011-09-22
BRPI0412007A (pt) 2006-08-15
EP1660655B1 (en) 2016-11-02
JP5358604B2 (ja) 2013-12-04
RU2005140664A (ru) 2007-08-27
ZA200510460B (en) 2006-11-29

Similar Documents

Publication Publication Date Title
CA2542192C (en) Look-through mutagenesis
US9012369B2 (en) Look-through mutagenesis for developing altered polypeptides with enhanced properties
WoÈrn et al. Stability engineering of antibody single-chain Fv fragments
US7175996B1 (en) Methods of optimizing antibody variable region binding affinity
Zhai et al. Synthetic antibodies designed on natural sequence landscapes
US20080153712A1 (en) Universal Libraries for Immunoglobulins
JP5143551B2 (ja) ユニバーサル抗体のライブラリー
Irving et al. Superseding hybridoma technology with phage display libraries
JP7337850B2 (ja) 抗体ライブラリー及びこれを用いた抗体スクリーニング方法
CA2482769A1 (en) "doping" in walk-through mutagenesis
MXPA06000080A (en) Look-through mutagenesis
AU8021900B2 (enExample)
Lai et al. Synthetic Antibody Engineering: Concepts and Applications

Legal Events

Date Code Title Description
EEER Examination request